The invention relates to the pharmaceutical industry and can be used in medical institutions for the treatment of tuberculosis. The anti-tuberculosis preparation comprises isoniazid, an inclusion complex of cyclodextrin with isoniazid in a molar ratio of 1:1, crospovidone with the trade mark "Polyplasdone XL-10" or croscarmellose sodium, mannitol or aspartame, lactose with the trade mark "SuperTab 14SD", bifendate, a mixture of calcium stearate and Aerosil in a weight ratio of 1:1, with the following ratio of components in the tablet, mg: isoniazid 85.0 - 95.0 inclusion complex of cyclodextrin with isoniazid 40.0 - 120.0 crospovidone with the trade mark "Polyplasdone XL-10" or croscarmellose sodium 45.0 - 70.0 mannitol or aspartame 30.0 - 60.0 lactose with the trade mark "SuperTab 14SD" 25.0 - 45.0 bifendate 3.0 - 5.0 mixture of calcium stearate and Aerosil in a weight ratio of 1:1 5.0 - 7.6. The process for preparing said preparation comprises successive mixing of isoniazid with an inclusion complex of cyclodextrin with isoniazid in a molar ratio of 1:1, crospovidone with the trade mark "Polyplasdone XL-10" or croscarmellose sodium, mannitol or aspartame, lactose with the trade mark "SuperTab 14SD", bifendate and adding a mixture of glidants (Aerosil and calcium stearate) for powdering the intermediate product and then tabletting said intermediate product by direct compression.Linvention se rapporte au domaine de lindustrie pharmaceutique et peut être utilisée dans des établissements médicaux afin de traiter la tuberculose. Cette préparation anti-tuberculose comprend de lisoniazide, un complexe comprenant de la cyclodextrine avec de lisoniazide selon un rapport en moles de 1 :1, de la crospovidone de la marque « Polyplasdone XL-10 » ou du croscarmellose sodique, du mannitol ou de laspartame, du lactose de la marque « SuperTab 14SD », du bifendate, un mélange de stéarate de calcium et daérosil selon un rapport en poids de 1 :1, les composants entrant dans la composi
